



ISIS-1169

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP NO. 1807

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cook and Manoharan

Serial No.: 08/117,363

Group Art Unit: 1807


Filed: September 3, 1993

Examiner: S. Houtteman


For: AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES

I, Joseph Lucci, Registration No. 33,307 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

On March 11, 1996


Joseph Lucci Reg. No. 33,307

Box AF
Assistant Commissioner for Patents
Washington DC 20231



AMENDMENT TRANSMITTAL LETTER

Transmitted herewith is an amendment in the above-identified application responsive to the Final Rejection dated December 11, 1995.

- (XX) Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted on **November 3, 1993**.
- () A verified statement claiming small entity status under 37 CFR 1.9 and 1.27 is enclosed.
- () Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR §§ 1.821 through 1.825.
- () No additional fee is required.

The fee for additional claims presented in this amendment has been calculated as follows:

				SMALL ENTITY			OTHER THAN SMALL ENTITY	
	Claims Remaining After Amendment	Highest Number Previously Paid for	No. Extra	Rate	Fee	OR	Rate	Fee
Total Claims	29	29 (at least 20)	0	x\$11=	\$ 0	OR	x\$22=	\$
Indep. Claims	2	3 (at least 3)	0	x\$39=	\$ 0	OR	x\$78=	\$
First Presentation Multiple Dependent Claims				+ \$125=	\$ 0	OR	\$250=	\$
Total fee for added claims:					\$ 0			\$

() Please charge my Deposit Account No. 23-3050 in the amount of \$_____. This sheet is attached in triplicate.

() A check in the amount of \$____ is attached. Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

(XX) The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.

(XX) Any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims.

(XX) Any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

(XX) The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 23-3050. This sheet is attached in triplicate.

(XX) Any patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20(d).

() The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

(XX) Any filing fees under 37 CFR 1.16 including fees for presentation of extra claims.

Date: March 11, 1996

Joseph Lucci
Signature
Joseph Lucci
Registration No. 33,307

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100



1513-1169

Code 2

Initial Review

BOX AF

1801

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP NO. 1807

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Cook and Manoharan

Serial No.: 08/117,363

Group Art Unit: 1807


Filed: September 3, 1993

Examiner: S. Houtteman

For: AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES

I, Joseph Lucci, Registration No. 33,307 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

On March 11, 1996


Joseph Lucci, Reg. No. 33,307

Box AF
Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

REQUEST FOR RECONSIDERATION

In response to the Office Action mailed December 11, 1995, in connection with the above-identified patent application, Applicants respectfully request that the following amendments be entered, without prejudice:

In the Claims:

Please rewrite claims 1 and 16 as indicated below:

1. (twice amended) A compound comprising a plurality of linked nucleosides, wherein:



15/3-2096
J.O